Introduction Biosplice Therapeutics is a company that specializes in medical research and development for tissue regeneration. Their platform is based on small molecule-based Wnt pathway modulation, which allows them to develop therapeutics for various degenerative diseases, regenerative medicine, and oncology. Similarly, Samumed has a unique operating philosophy that focuses on creating a broad technology platform to modulate regenerative pathways and enhance patient health. This approach aims to address a wide range of medical conditions and improve overall well-being. |
Disease Domain | Count |
---|---|
Neoplasms | 1 |
Hemic and Lymphatic Diseases | 1 |
Nervous System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 3 |
Top 5 Target | Count |
---|---|
DYRK1A x DYRK1B | 1 |
CLK2 x DYRK1A | 1 |
CLK x DYRK | 1 |
Target |
Mechanism CLK2 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism DYRK1A inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CLK inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date18 Nov 2022 |
Sponsor / Collaborator |
Start Date03 Nov 2021 |
Sponsor / Collaborator |
Start Date15 Jul 2021 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Lorecivivint ( CLK2 x DYRK1A ) | Osteoarthritis, Knee More | Phase 3 |
Cirtuvivint ( CLK x DYRK ) | Hematologic Neoplasms More | Preclinical |
SM15685 ( DYRK1A x DYRK1B ) | Alzheimer Disease More | Preclinical |
SM-04646 ( Wnt ) | Idiopathic Pulmonary Fibrosis More | Discontinued |
SM-09419 ( CLK ) | Mantle-Cell Lymphoma More | Discontinued |